Dies ist eine Übersichtsseite mit Metadaten zu dieser wissenschaftlichen Arbeit. Der vollständige Artikel ist beim Verlag verfügbar.
Phase III Trial of Carboplatin and Paclitaxel Compared With Cisplatin and Paclitaxel in Patients With Optimally Resected Stage III Ovarian Cancer: A Gynecologic Oncology Group Study
2.049
Zitationen
10
Autoren
2003
Jahr
Abstract
In patients with advanced ovarian cancer, a chemotherapy regimen consisting of carboplatin plus paclitaxel results in less toxicity, is easier to administer, and is not inferior, when compared with cisplatin plus paclitaxel.
Ähnliche Arbeiten
Integrated genomic analyses of ovarian carcinoma
2011 · 8.042 Zit.
Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS)
2003 · 5.959 Zit.
Integrated genomic characterization of endometrial carcinoma
2013 · 5.663 Zit.
Ovarian cancer statistics, 2018
2018 · 3.671 Zit.
Average Risks of Breast and Ovarian Cancer Associated with BRCA1 or BRCA2 Mutations Detected in Case Series Unselected for Family History: A Combined Analysis of 22 Studies
2003 · 3.660 Zit.